Pulsify Medical

Key People

• Iwan van Vijfeijken - CEO
• Steve Stoffels - VP Technology
• Jan Dhooge - Co-founder
• Lieven Herbots - Co-founder
• Xavier Rottenberg - Co-founder

Assessment

Team

Aspect: First-time 10+ yrs
Summary: The leadership team comprises individuals with over 10 years of experience in their respective fields, including medical technology and research.

The leadership team's background includes significant experience in medical technology and research, contributing to the company's innovative developments in wearable ultrasound technology.

Clinical Need

Aspect: Very Strong
Summary: There is a significant unmet need for continuous, non-invasive cardiac monitoring in both hospital and home settings.

Current solutions for cardiac monitoring are often invasive or lack continuous monitoring capabilities. Pulsify Medical's wearable ultrasound patch aims to fill this gap by providing real-time, non-invasive monitoring, which is crucial for patients with cardiovascular diseases.

Competition

Aspect: First mover
Summary: Pulsify Medical is among the first to develop a wearable ultrasound patch for continuous cardiac monitoring.

While traditional ultrasound devices exist, they are typically handheld and not suitable for continuous monitoring. Pulsify Medical's innovation in creating a wearable patch positions them ahead of competitors in this niche market.

Technical Challenge

Aspect: Complex
Summary: Developing a flexible, wearable ultrasound patch involves significant technical challenges.

Integrating flexible ultrasound transducers into a wearable patch requires advanced materials and engineering solutions. Ensuring consistent performance and reliability adds to the technical complexity.

Patent

Aspect: Strong
Summary: The company holds strong intellectual property from both imec and KU Leuven.

Leveraging imec's flexible ultrasound transducer technology and KU Leuven's expertise in cardiac imaging provides Pulsify Medical with a robust patent portfolio, safeguarding their innovations.

Financing

Aspect: Well-funded
Summary: The company has secured significant funding from reputable investors.

Pulsify Medical has raised 2.6 million in seed funding and an additional 5.4 million in Series A funding, totaling 8 million. Investors include imec.xpand, KU Leuven, University Hospitals Leuven, PMV, Gemma Frisius Fund, and imec.

Regulatory

Aspect: Running FIH
Summary: The company is conducting first-in-human clinical trials.

Pulsify Medical is in the early stages of clinical validation, with first-in-human trials underway. Successful completion is critical for regulatory approval and subsequent market entry.

Opportunity Rollup

Odds of Success

3.85

Peak Market Share

5.75

Segment CAGR

3.6%

Market Segment

Cardiovascular Devices

Market Sub Segment

Patient Monitoring

Key Takeaway

Pulsify Medical's innovative wearable ultrasound patch addresses a significant unmet need in continuous cardiac monitoring, positioning the company favorably in a growing market.